[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584943":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":40,"locations":46,"responsibleParty":68,"collaborators":11,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":11,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":11,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":11,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Shanghai Hengrui Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL",null,[13,14,15,16,17],"Drug: SHR-A2102","Drug: Bevacizumab Injection","Drug: Adebelimab Injection","Drug: Ametinib Mesylate Tablets","Drug: Osimertinib Mesylate Tablets",[19,24,28,32,36],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","SHR-A2102","SHR-A2102 for injection.",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Bevacizumab Injection","Bevacizumab injection.",[9],{"type":20,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"Adebelimab Injection","Adebelimab injection.",[9],{"type":20,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"Ametinib Mesylate Tablets","Ametinib mesylate tablets.",[9],{"type":20,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"Osimertinib Mesylate Tablets","Osimertinib mesylate tablets.",[9],[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Yang Wu","CONTACT","+86-0518-82342973","yang.wu.yw96@hengrui.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Shanxi Cancer hospital","RECRUITING","Taiyuan","Shanxi","030001","China","CN",{"type":56,"coordinates":57},"Point",[58,59],112.56028,37.86944,{"lat":59,"lon":58},[62,66],{"name":63,"role":43,"phone":64,"phoneExt":11,"email":65},"Jie Wang","+86-0351-4881611","zlhuxi@163.com",{"name":63,"role":67,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":69,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100584943","phase-2-a-trial-of-shr-a2102-with-other-antitumor-therapies-in-advanced-solid-tumors-100584943",false,"NCT06895928","A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. The age of signing the informed consent is 18 -70 years, regardless of gender.\n2. At least one measurable lesion according to RECIST v1.1 criteria.\n3. The ECOG score is 0 or 1.\n4. Expected survival ≥12 weeks.\n5. Good level of organ function.\n6. Have the ability to give informed consent and to comply with the treatment plan.\n7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.\n\nExclusion Criteria:\n\n1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.\n2. Spinal cord compression not cured by surgery and\u002For radiotherapy.\n3. Subjects with uncontrolled tumor-related pain.\n4. Received antitumor therapy within 4 weeks before the start of the study.\n5. Subjects with severe cardiovascular and cerebrovascular disease.\n6. History of immunodeficiency, including a positive HIV test.","ALL","18 Years","70 Years",{"count":81,"type":82},400,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.",[88],"Advanced Solid Tumors","2025-04-21",{"date":91,"type":92},"2025-04-22","ACTUAL",{"date":94,"type":92},"2025-03-28",{"date":96,"type":82},"2028-12",{"name":5,"class":6},1]